Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy

NCT06443606 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

108

Enrollment

OTHER

Sponsor class

Conditions

BPC
Non Optimal Response to UDCA

Interventions

DRUG: Bezafibrate 400 mg in addition to UDCA therapy
DRUG: Bezafibrate 200 mg in addition to UDCA therapy
DRUG: Placebo in addition to UDCA therapy

Sponsor

Assistance Publique - Hôpitaux de Paris